{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:33:56Z","timestamp":1793010836592,"version":"4.5.0"},"reference-count":0,"publisher":"The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Biology"],"abstract":"<jats:p>Background\/aim: High-grade serous ovarian cancer (HGSOC) remains one of the most aggressive forms of ovarian malignancy and frequently shows resistance to conventional therapies. This study aimed to synthesize a novel series of purine analogues, 6-[(4-substituted\u00a0benzyl amine)\/(4-substituted aniline)]-9-cyclopentyl purines, and evaluate their anticancer efficacy against HGSOC cell lines.\nMaterials and methods:  We assessed the biological effects of the synthesized purine analogues on the OVCAR3, OVSAHO, and KURAMOCHI HGSOC cell lines using the sulforhodamine B assay. To investigate the mechanism of action, we conducted flow cytometry and western blot analyses, focusing on DNA replication and apoptosis.\nResults: Among the tested compounds, compound 8 showed significant cytotoxic activity with IC50 values in the low micromolar range. Preliminary data from flow cytometry and western blot analyses indicated that compound 8 may inhibit DNA replication and induce apoptosis, as reflected by changes in cell viability and cell-cycle progression.\nConclusion: Compound 8 may disrupt key proliferative mechanisms in cancer cells by interfering with DNA synthesis and activating programmed cell death pathways. These findings suggest that compound 8 is a promising lead candidate for further development in ovarian cancer therapeutics.<\/jats:p>","DOI":"10.55730\/1300-0152.2788","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:15:52Z","timestamp":1772190952000},"page":"29-36","source":"Crossref","is-referenced-by-count":0,"title":["Biological evaluation of novel 6,9-disubstituted purine analogues in high-grade\u00a0serous ovarian cancer cell lines"],"prefix":"10.55730","volume":"50","author":[{"given":"DUYGU","family":"ALTIPARMAK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEREN","family":"DEM\u0130REL YAVUZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PINAR","family":"KUL KARADEN\u0130ZL\u0130","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130REM","family":"DURMAZ \u015eAH\u0130N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MERAL","family":"TUN\u00c7B\u0130LEK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"34691","published-online":{"date-parts":[[2026,2,23]]},"container-title":["Turkish Journal of Biology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T09:52:10Z","timestamp":1793008330000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.tubitak.gov.tr\/biology\/vol50\/iss1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.55730\/1300-0152.2788","relation":{},"ISSN":["1300-0152"],"issn-type":[{"value":"1300-0152","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]}}}